Aptar Pharma announces its acquisition of the clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. This strategic move strengthens Aptar’s support for early-stage drug development by offering formulation, fill and finish services for Phase 1 and 2 clinical trials and enhances adoption of its proprietary devices in early-stage clinical programs..

Aptar Pharma宣布从SWK Holdings收购Mod3 Pharma（前身为Enteris Biopharma）的临床试验材料生产能力。这一战略性举措通过为1期和2期临床试验提供配方、填充和成品服务，加强了Aptar对早期药物开发的支持，并推动其专有设备在早期临床项目中的应用。

This acquisition builds on a successful collaboration between Aptar Pharma and Mod3 Pharma, particularly in serving Aptar Pharma customers with Phase 1 and Phase 2 cGMP fill and finish services for orally inhaled nasal drug products (OINDPs), filling a largely unmet need in the market. The capabilities acquired also help Aptar address a growing market demand for agile, high-quality Current Good Manufacturing Practices (cGMP) clinical trial material supply services that complement the segment’s existing service offerings.

此次收购建立在Aptar Pharma与Mod3 Pharma成功合作的基础上，特别是在为Aptar Pharma客户提供口服吸入鼻腔药物产品（OINDPs）的1期和2期cGMP填充和完成服务方面，满足了市场上很大程度未被满足的需求。所获得的能力还帮助Aptar应对市场对灵活、高质量的现行良好生产规范（cGMP）临床试验材料供应服务日益增长的需求，这些服务是对该细分市场现有服务的良好补充。

Additionally, the acquisition accelerates the adoption of new drug delivery technologies, initially focusing on OINDPs, with potential expansion into dermal, ophthalmic, injectable and secondary packaging solutions using Aptar’s active material science solutions..

此外，此次收购加快了新药物输送技术的采用，最初重点放在口服吸入性药物产品（OINDPs）上，并有可能利用Aptar的活性材料科学解决方案扩展到皮肤、眼科、注射剂和二级包装解决方案。

Aptar Pharma will now operate an FDA-inspected, state-of-the-art facility in Boonton, New Jersey. The site includes cGMP cleanrooms, high-potency Active Pharmaceutical Ingredient (API) suites, biologics capabilities, and advanced fill-finish technologies – fully aligned with Aptar Pharma’s drug delivery solutions portfolio..

Aptar Pharma现在将在新泽西州布恩顿运营一家经FDA检查的、最先进的设施。该场地包括符合cGMP标准的洁净室、高效活性药物成分（API）套间、生物制品能力以及先进的填充-完成技术，完全与Aptar Pharma的药物输送解决方案组合保持一致。

Gael Touya, President of Aptar Pharma, commented, “Our vision at Aptar Pharma is clear: From formulation to patient. By integrating Phase 1 and 2 clinical manufacturing capabilities, we’re not just expanding our technical footprint – we’re deepening our commitment to customers seeking a seamless and accelerated path to market.

阿普塔制药公司总裁高兰·图亚评论道：“我们在阿普塔制药的愿景很明确：从配方到患者。通过整合第一和第二阶段临床生产的能力，我们不仅扩大了我们的技术足迹，还加深了我们对寻求无缝且加速上市途径的客户的承诺。”

This move reinforces our position as a trusted partner from molecule to delivery, and ultimately, to the patient.”.

这一举措巩固了我们作为从分子到交付，最终到患者的可信赖合作伙伴的地位。

Sai Shankar, President, M&A, Strategy, Business Development, Marketing, Drug Services, added, “We’re expanding our niche services to help customers move faster in areas of unmet need, and without duplicating the strengths of our trusted partners. This strategic expansion of our services builds on our legacy in drug dosing and dispensing systems by integrating deeper expertise as a drug delivery innovator, as well as product development and formulation, allowing us to offer more specialized and holistic support to our customers.”.

赛尚卡尔，总裁，兼并收购、战略、业务发展、市场营销、药品服务部门补充道：“我们正在扩展我们的专业服务，以帮助客户在未满足需求的领域更快地推进，同时不重复我们信赖的合作伙伴的优势。我们服务的战略性扩展基于我们在药物剂量和分配系统方面的传统，通过整合更深入的专业知识作为药物传递创新者，以及产品开发和配方，使我们能够为客户提供更专业和全面的支持。”

Dr. Paul Shields, CEO of Mod3 Pharma, remarked, “We are delighted to become part of the Aptar family. This acquisition reflects our shared commitment of accelerating the development of innovative therapies and bringing them to patients faster.”

Mod3 Pharma首席执行官保罗·希尔兹博士表示：“我们很高兴成为Aptar家族的一员。此次收购体现了我们共同致力于加速创新疗法的开发，并更快地将其带给患者。”

Source: aptar.com

来源：aptar.com